Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review.

Alessandra Cassano, Sabrina Rossi, Giovanni Schinzari, Michele Basso, Antonia Strippoli, Vincenzo Dadduzio, Ettore D'Argento, Carlo Antonio Barone

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Abstract Endocrine treatment is the first-line therapy in hormone-sensitive metastatic breast cancer while chemotherapy is the first option in tumors refractory to endocrine therapy and in hormone-negative disease. Optimal duration, efficacy and safety of a maintenance endocrine therapy or chemotherapy after an induction treatment are still a matter of debate. We performed a literature review to identify studies regarding maintenance hormonal and chemotherapy treatments in metastatic breast cancer. We analyzed data relating to efficacy (improvement of progression-free survival and overall survival) and safety (symptoms relief and quality of life [QoL]). Maintenance endocrine therapy could prolong progression-free survival with a better control of symptoms and improving QoL. Maintenance chemotherapy prolong the response to a previous treatment, worsening the QoL, except for metronomic capecitabine.
Original languageEnglish
Pages (from-to)1299-1307
Number of pages9
JournalFuture Oncology
Publication statusPublished - 2016

Keywords

  • Maintenance

Fingerprint

Dive into the research topics of 'Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review.'. Together they form a unique fingerprint.

Cite this